A while back, PDMI delivered three of their ”Photon” systems to France of which one of those systems were used to perform a live surgery teaching Seminar at the prestigious Rothschild Eye Institute in Paris. Anyone doing some DD on Rothschild should know the magnitude of such an event happening and the credibility it adds to PDMI by reviewing the website below:
It was also reported that 25 distributors representing 30 different countries in Europe and North Africa have either contracted, or are in the process of finalizing agreements for representing the product in their respective countries. Again, this was a while back so I’m expecting that updates could be pending on this too along with other things.
SHEFF DD Alert (Post #2 of 2) PDMI at .0015 on 10/8/09. PDMI is significantly undervalued compared to other companies in its space. Could easily be a .03 to .05 cent stock based on potential and what the company has in the pipeline. PDMI time is now in the 4th Quarter of 2009. PDMI could be a significant buyout target for big Pharma (Alcon or Bausch & Lomb). Key Forward Looking Events for PDMI are 1) They have Multiple ophthalmic products, 2) 1 pending FDA decision per 10Q (Sales of surgical products are at a standstill pending FDA approval of the Photon TM laser system), and 3) CPT-11 code for reimbursement (“ The Blood Flow Analyzer™ is expected to have a new CPT reimbursement code for Medicare insurance providers issued before the end of 2009”). 4) A big boon for the company is that Paradigm Medical has announced plans to Release Its New Corneal Topographer, the Paravue, in the United States Market! That will occur in the 4th quarter.
52 wk high is ..055 & 52 wk low is .0009. Closer to the low than high and this has much more potential than 1 yr ago!
MEDICAL RUNNERS IN 2009 BIEL.PK from .0013 in May to .12 in September w/ Caveat Emptor on pink sheets. 1.5 bill auth and o/s is that was almost maxed. PDMI is fully-reporting on the pink sheets!
ASFX.PK from .002 in August to .08 in September NEPH.OB from .06 in April to $2.40 in September 09 NPHC.OB from .05 in August to $1.00 in September 09 PWRM.OB from .014 in August to .15 in September 09 IMGG from .05 in August to .54 in September XCHO from .012 in August to .17 in September LLBO.PK from .0018 to .018 in August w/5 bill auth shares and o/s almost maxed out w/ only 1 product.
Recent runners- LLBO recently ran from .001 to .018 on news that they were going to file for their First Warning Breast Cancer Detection. They have 5 billion A/S and actively dilute shares to obtain cash for the company. They are currently about (.005) cents right now. PWRM ran from .018 to .15 in two weeks on clinical markers for Alzheimer’s Disease and Breast Cancer. NPHC recently went from .05 to .95 based on a product not even available yet but with a lot of potential! They also have a much larger share structure. MEDICAL COMPANIES ARE BLAZING HOT in this Medical Enviroment now. PDMI is not on the radar and should be with the significant events that are forthcoming in this 4th quarter based on their 10Q as the quarter just started on Oct 1st.
Share Structure (From Latest 10Q period ending 3/31/09) Auth 1.4 Billion O/S 519,251, 922 Float Recent 8-k The Company's Board of Directors made this decision to voluntarily deregister the Company's common stock based on several factors, including the costs of preparing and filing periodic reports with the SEC, and the elimination of the substantial legal, audit, and other costs associated with being a reporting company. The Board of Directors determined that the increasing financial costs and commitment of management's time to ongoing SEC reporting and complying with the many new regulations that have been adopted is not justified in the Company's circumstances. The Board of Directors believes that freeing up these resources will create value for the Company's shareholders by allowing management to better prepare and execute strategic plans, and improve the Company's long-term financial strength. http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6741933 Clinical studies on Photo will result from saving Photon Laser System and new inline products like Paravue will benefit significantly from savings the company will have. BIEL did the same thing with the Actipatch when cash was running low. They missed their filing and went into (CE) Caveat Emptor Status until last week where they are now fully reporting. There stock went from .0013 in May to .12 in Sept 09. PDMI is still reporting on the pink sheets. Paradigm Medical Announces Plans to Release Its New Corneal Topographer, the Paravue, in the United States Market Paradigm Medical Industries, Inc. (OTCBB: PDMI) announced today that the Company will soon begin to introduce the first of its four new ophthalmic diagnostic devices, the Paravue, during the remainder of 2009. The Paravue is a sophisticated topographer utilizing Placido Disk Technology and an advanced software to provide accurate and detailed analysis of the anterior corneal surface. Market Wire, June, 2009 http://findarticles.com/p/articles/mi_pwwi/is_200906/ai_n31922569/
PDMI: 2000-2008 Synopsis of Defense Contracts
Paradigm Medical Industries Defense Contracts Awarded from 2000-2008 Total: 3 Amount: $88,880
Paradigm Medical Industries Julio Maximo Vice President of Operations (801) 977-8970 ext. 643
On June 1st, Paradigm announced plans to release the first of four new ophthalmic diagnostic devices, the Paravue, in the United States. The sophisticated corneal topographer utilizes Placido Disk Technology and advanced software to provide an accurate and detailed analysis of the anterior corneal surface, making it a valuable addition to optometric and ophthalmic clinics. Last month, Paradigm also announced plans to begin clinical work to upgrade its Blood Flow Analyzer device from an Investigational to a Reimbursable level. The move could dramatically improve the device’s marketability as patients could be reimbursed by regional medical insurance companies for testing using the Blood Flow Analyzer.
We specialize in the development and marketing of diagnostic equipment for the ophthalmic market. Our product families of topographers, autoperimeters and ultrasonic biomicroscopes combined withour unique Blood Flow Analyzer help the eye care professionals community diagnose and treat disorders of the eye such as glaucoma, cataracts and age-related macular degeneration.
Sales of the P60 UBM Ultrasound Biomicroscope increased by $68,000 to $73,000, or 44% of total revenues, for the three months ended March 31, 2009, compared to $5,000, or 2% of total revenues, for the same period in 2007. Sales of the Blood Flow Analyzer™ increased by $11,000 to 14,000 or 9% for the three months ended March 31, 2009, compared to net sales of $3,000, or 1% of total revenues, during the same period in 2008. Sales from the P2700, P37, and P37-II A/B Scan Ocular Ultrasound Diagnostic devices decreased by $34,000 to $7,000, or 5% of total revenues for the three months ended March 31, 2009, compared to $41,000, or 18% of total revenues for the same period in 2008. Sales of the P55, P2200, P2500 Pachymetric Analyzers, and the P2000 A-Scan Biometric Ultrasound Analyzer decreased by $7,000 to $0 or 0% of total revenues, for the three month period ended March 31, 2009, compared to $7,000, or 3% of total revenues, for the same period in 2008. Combined sales of the LD 400, TKS 5000, and CT200 Autoperimetry Systems decreased by $97,000 to $33,000, or 22% of the total revenues, for the three months ended March 31, 2009, compared to $130,000, or 57% of total revenues, for the same period in 2008.
Sales of the Blood Flow Analyzer TM decreased due in part from the reorganization of the Company's sales force. The Company anticipates continuing the upward trend in Blood Flow Analyzer TM sales through additional efforts by the Company to gain more wide spread support from the Blood Flow Analyzer TM through increased clinical awareness, product development and improved marketing plans.
Sales of surgical products are at a standstill pending FDA approval of the Photon TM laser system. In the twelve month period ended December 31, 2008, the Company realized no sales in the surgical line consisting of the Photon TM laser system. There were also no sales in the surgical line for the comparable period of 2007.
The Company anticipates reversing the downward trend in sales through additional efforts by the Company to gain more widespread support for the P60 UBM Ultrasound Biomicroscope, the Blood Flow Analyzer™, the LD400 Antoperimetry System, the P37-II Ocular Ultrasound Diagnostic A/B Scan, the 2200 and 2500 Pachymetric Analyzers, the P2000 A-Scan Biometric Ultrasound Analyzer, the new agreement with the Costrugione Srumenti Oftalmici ("CSO") organization and its ophthalmic products, and through increased clinical awareness, ongoing product development, improved marketing plans and strategic product replacement, and ongoing development of the LD400 perimeter. The Blood Flow Analyzer™ is expected to have a new CPT reimbursement code for Medicare insurance providers issued by the end of 2009, reversing the downward sales trend it has experienced.
This company will move higher based on potential and the cost of its medical devices. This company is in poor financial situation and owes convertible debts to 4 accredited investors. It is a pink sheet with significant potential that can change its fortune overnight with an FDA Decision or if any or all of the forward-looking statements come true. This is a definite diamond in the rough just like other medical companies that I have discussed in this post.
News 
Market Data 
Discover 
